Emerald Health Therapeutics Receives Court Approval of Plan of Arrangement with Skye Bioscience

Stock Information for SpeakEasy Cannabis Club Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About SpeakEasy Cannabis Club Ltd.

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting
Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model
Skye Completes 26-week Treatment Phase in Phase 2a CBeyond(TM) Study
Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond(TM) Phase 2a Topline Clinical Data Readout
Skye Bioscience to Participate in Upcoming Investment and Medical Conferences
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
Skye Bioscience Shares Nimacimab "Anatomy of Progress" Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.